Dompe' Farmaceutici S.p.A. — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

3 Recruiting

5 Completed trials

12 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II: 7 Phase I: 1 Phase I (Other): 1

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Atopic keratoconjunctivitis 2 Acute respiratory distress syndrome 1 Dry eye 1 Type 1 diabetes mellitus 1 Cystitis interstitial 1 Cerebral palsy 1 Persistent corneal epithelial defect 1 Eye inflammation 1

Top IMPs

CENEGERMIN 4 (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-ETHYL-34-[(E,2R)-HEX-4-EN-2-YL]-4,7,10,12,15,19,25,28-OCTAMETHYL-33-(METHYLAMINO)-6,9,18,24-TETRAKIS(2-METHYLPROPYL)-3,21-DI(PROPAN-2-YL)-1-OXA-4,7,10,13,16,19,22,25,28,31-DECAZACYCLOTETRATRIACONTANE-2,5,8,11,14,17,20,23,26,29,32-UNDECONE HYDROCHLORIDE 2 KETOPROFEN LYSINE 1 KETOPROFEN LYSINE, GABAPENTIN 1 LADARIXIN 1 OXYBUPROCAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE 1 PARACETAMOL 1 REPARIXIN 1

All trials

11 total

Proof-of-Concept Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of Intranasal Cenegermin in Adult Participants … Pending

2025-522692-29-00 Phase II 8 countries CENEGERMIN
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants Pending

2025-522935-32-00 Phase I (Other) 1 country
An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Pending

2025-523443-35-00 Phase III 8 countries CENEGERMIN; OXYBUPROCAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers Recruiting

2025-524527-46-00 Phase I 1 country
Intranasal Cenegermin in Pediatric Participants with Spastic Cerebral Palsy. Recruiting

2025-522786-29-00 Phase II 1 country CENEGERMIN
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution… Recruiting

2025-522291-83-00 Phase III 2 countries (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-ETHYL-34-[(E,2R)-HEX-4-EN-2-YL]-4,…
A study to evaluate safety and efficacy of two different concentrations of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF… Ended

2023-507561-26-00 Phase II 1 country CENEGERMIN
A study to evaluate safety and efficacy of two different doses of Isocyclosporin A eye drop solution in patients with Atopic Keratoconjuncti… Ended

2023-508907-19-00 Phase II 1 country (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S,34R)-30-ETHYL-34-[(E,2R)-HEX-4-EN-2-YL]-4,…
Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy … Ended

2024-512621-88-00 Phase II 2 countries REPARIXIN
A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two d… Ended

2024-513940-27-00 Phase II 2 countries KETOPROFEN LYSINE; KETOPROFEN LYSINE, GABAPENTIN; PARACETAMOL
Study to evaluate the effect and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes Ended

2024-513560-26-00 Phase II 3 countries LADARIXIN

Showing 1–11 of 11 trials

← All sponsors A–Z